UID262611
阅读权限200
专业分
贡献分
爱医币
鲜花
注册时间2006-12-10
|
参考文献
1. Alexander JP Jr, Baden L, Pallansch MA, et al. Enterovirus 71 infection and neurologic disease-United States, 1977-1991[J]. J Infect Dis, 1994, 169(4): 905-908.
2. Guan D, Vander Sanden S, Zeng H, et al. Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in **, 1998-2010[J]. PLoS One, 2012, 7(9):e44386.
3. Zhang Y, Tan X, Cui A, et al. Complete genome **ysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14years[J]. PLoS One, 2013, 8(2): e56341.
4. Chang LY, Huang YC, Lin TY. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease[J]. Lancet, 1998, 352(9125): 367-368.
5. Centers for Disease Control and Prevention (CDC). Nonpolio enterovirus and human parechovirus surveillance -- United States, 2006-2008[J]. MMWR Morb Mortal Wkly Rep,2010, 59(48): 1577-1580.
6. Li YP, Liang ZL, Xia JL, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II,Randomized, double-blind,placebo-controlled trial[J]. J Infect Dis, 2014, 209(1): 46-55.
7. Chang SC, Li WC, Chen GW, et al. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative **ysis of complete genomes[J]. J Med Virol,2012, 84(6): 931-939.
8. Brown BA, Oberste MS, Alexander JP Jr, et al. Molecular epidemiology and evolution ofenterovirus 71 strains isolated from 1970 to 1998[J]. J Virol, 1999, 73(12): 9969-9975.
9. Cardosa MJ, Perera D, Brown BA, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative **ysis of the VP1 andVP4 genes[J]. Emerg Infect Dis, 2003, 9(4):461-468.
10. Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group[J]. Clin Infect Dis, 2000, 31(3): 678-683.
11. Huang YP, Lin TL, Kuo CY, et al. The circulation of subgenogroups B5 and C5 of enterovirus
71 in Taiwan from 2006 to 2007[J]. Virus Res, 2008, 137(2): 206-212.
12. Huang Y, Zhou Y, Lu H, et al. Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009-2013[J]. J Med Virol, 2015, 87(9): 1471-1479.
13. 邓爱萍, 张永慧, 孙立梅, 等. 广东省健康人群HFMD 病原隐性感染状况调查[J]. 中华流行病学杂志, 2012, 33(2): 189-191.
14. 张东晓, 杨帆, 王冰, 等. 深圳市社区人群EV71 和CoxA16 隐性感染的流行病学分析[J].中国热带医学, 2011, 11(11): 1332-1333.
15. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan[J]. N Engl JMed, 1999, 341: 929-935.
16. Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71[J]. Lancet Neurol, 2010, 9(11): 1097-1105.
17. Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan[J]. JAMA, 2004, 291: 222-227.
18. Merovitz L, Demers AM, Newby D, et al. Enterovirus 71 infections at a Canadian center[J].Pediatr Infect Dis J, 2000, 19: 755-777.
19. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance[J]. FEMS Microbiol Rev, 2002, 26: 91-107.
20. 卫计委. 《HFMD 诊疗指南(2010 年版)》. 卫发明电〔2010〕38 号.
21. Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: aprospective clinical, virological, and molecular epidemiological study[J]. Clin Infect Dis, 2007,44: 646-656.
22. Ooi M, Wong S, Mohan A, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak[J].BMC Infect Dis, 2009, 9: 3.
23. Lu HK, Lin TY, Hsia SH, et al. Prognostic implications of myoclonic jerk in children with enterovirus infection[J]. J Microbiol Immunol Infect, 2004, 37: 82-87.
24. 国家卫生和计划生育委员会. 《HFMD 监测试点运行方案》. 国卫办疾控函〔2015〕820号.
25. Schmidt N, Lennette E, Ho H. An apparently new enterovirus isolated from patients with disease of the central nervous system[J]. J Infect Dis, 1974, 129: 304-309.
26. Hand, foot and mouth disease in Japan, 2002–11: IASR, 2012.
27. Chan KP, Goh KT, Chong CY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore[J]. Emerg Infect Dis, 2003, 9(1): 78-85.
28. Zhang Y, Tan XJ, Wang HY, et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C 4 of human enterovirus 71 in Shandong, China[J]. J Clin Virol, 2009, 44: 262-267.
29. Zhang Y, Zhu Z, Yang WZ, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China[J]. Virol J, 2010,7: 94.
30. 周伯平, 李成荣.肠道病毒71 型HFMD[M].北京: 人民卫生出版社, 2009: 45.
31. Yang B, Wu P, Wu JT, et al. Seroprevalence of enterovirus 71 antibody among children in China:a systematic review and meta-**ysis[J]. Pediatr Infect Dis J, 2015, 34(12): 1399-1406.
32. Li L, Yin HZ, An ZJ, et al. Considerations for developing an immunization strategy with enterovirus 71 vaccine[J]. Vaccine, 2015, 33(9): 1107-1112.
33. Wang ZL, Xia AM, Li YF, et al. Socioeconomic burden of hand, foot and mouth disease in children in Shanghai, China[J]. Epidemiol Infect, 2016, 144(1): 138-143.
34. Gan ZK, Jin H, Li JX, et al. Disease burden of enterovirus 71 in rural central China: A community-based survey[J]. Hum Vaccin Immunother, 2015, 11(10): 2400-2405.
35. Edmond Ma, Connie Fung Steven H. L. Yip,et al. Estimation of the Basic Reproduction Number of Enterovirus71 and Coxsackievirus A16 in Hand, Foot, and Mouth Disease Outbreaks[J]. Pediatr Infect Dis J 2011;30: 675–679.
36. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med, 2014, 370(9): 818-828.
37. Hu YM, Wang X, Wang JZ, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months[J]. Clin Vaccine Immunol, 2013, (12): 1805-1811.
38. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9882): 2024-2032.
39. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med, 2014, 370(9): 829-837.
40. Mao Q, Wang Y, Shao J, et al. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals[J]. Hum VaccinImmunother, 2015,11(11):2723-2733.
41. Mao Q, Cheng T, Zhu F, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children[J]. PLoS One, 2013, 8(11): e79599.
42. Zhang H, An D, Liu W, et al. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71pseudovirus-based assay[J]. PLoS One, 2014, 9(6): e100545.
43. Liu LD, Mo ZJ, Liang ZL, et al. Immunity and clinical efficacy of an inactivated enterovirus 71vaccine in healthy Chinese children: a report of further observations. BMC Medicine. 2015,17(13):226.
44. 卫计委.《预防接种工作规范》.卫疾控发[2005]373 号.
45. 国家卫生和计划生育委员会.《全国疑似预防接种异常反应监测方案》.卫办疾控发〔2010〕94 号
|
|